Full Course Description

COPD Prescribing Transformed: Biomarkers, And What Comes Next

Chronic obstructive pulmonary disease (COPD) management is rapidly evolving, and many clinicians are still using outdated prescribing approaches. The 2026 GOLD updates shift decision-making toward symptom burden, exacerbation risk, and biomarker-guided care, while emerging therapies like dupilumab are changing the treatment landscape. Without a clear approach, clinicians may overuse inhaled corticosteroids, miss opportunities to escalate therapy appropriately, or struggle to individualize care.

This session delivers practical, prescriptive strategies you can apply immediately in primary care. Learn how to use ABE classification, interpret blood eosinophils to guide therapy, and confidently select between dual, triple, and emerging treatments. Through real-world cases and clinical pearls, you will leave with a clear, evidence-based approach to optimizing COPD outcomes.

Program Information

Objectives

Analyze 2026 GOLD updates and apply biomarker-driven strategies, including blood eosinophils, to individualize COPD pharmacotherapy and optimize initial and follow-up treatment decisions.
Evaluate evidence for dual, triple, and emerging therapies to make risk-benefit-informed prescribing decisions that reduce exacerbations and improve patient outcomes in complex, real-world patients.

Outline

COPD Assessment and Initial Treatment (2026 GOLD Updates)

ABE classification: Symptom burden and exacerbation risk
Blood eosinophils as a prescribing biomarker
Initial therapy selection: Bronchodilator strategies

Optimizing Pharmacotherapy and Escalation Strategies

Follow-up pathways: Dyspnea vs exacerbation predominant symptoms
Dual vs triple therapy: Indications and outcomes data
Appropriate ICS use and de-escalation considerations
Add-on therapies: Roflumilast, azithromycin, ensifentrine
Biologics in COPD: Dupilumab and evolving evidence

Practical Prescribing in Primary Care

Inhaler device selection and technique considerations
Adherence barriers and patient-centered strategies
Management of exacerbations: Steroids, antibiotics, follow-up
Comorbidities and COPD: Cardiovascular disease, smoking cessation

Limitations and Clinical Considerations

Limitations of the research and evolving evidence base
Risks of therapy: ICS-related pneumonia, biologic safety considerations
Cost, access, and real-world implementation challenges
Shared decision-making and individualized care approaches

Target Audience

NPs
APRNs
CNSs
PAs
MDs
PharmDs – Primary Care/Family Practice

Copyright : 09/24/2026

Advanced Pharmacotherapy for Midlife Women’s Health – Practical Prescribing for VMS, GSM, Mood, Sleep, Libido, and Bone

Menopause care is evolving rapidly, yet many clinicians still report gaps in training, confidence, and practical prescribing strategies. Educational deficits contribute to undertreatment, confusion regarding hormone therapy safety, and inconsistent use of nonhormonal options. This creates a significant practice gap in primary care and women's health, where clinicians are expected to manage vasomotor symptoms, genitourinary syndrome of menopause, sleep disruption, mood changes, sexual concerns, and long-term health implications with increasing precision.

This advanced pharmacology-focused seminar is designed for experienced clinicians who strive for a practical, evidence-based approach to modern midlife prescribing. Learn how to choose from systemic estrogen formulations, progesterone and progestin options, local vaginal therapies, nonhormonal prescription agents, and symptom-targeted adjunctive medications. Jaclyn “Jackie” Piasta, DNP, WHNP-BC, MSCP, will emphasize clinical decision-making, safety, contraindications, special populations, and real-world case applications to prescribe with greater precision and confidence.

Program Information

Objectives

Analyze current evidence and risk-stratification principles to select individualized pharmacotherapy for menopausal and perimenopausal patients with vasomotor, genitourinary, sleep, mood, and sexual symptoms.
Apply advanced prescribing strategies to compare hormonal and nonhormonal options, account for contraindications and comorbidities, and reduce medication-related risk in complex midlife patients.

Outline

Menopause Pharmacology: What Matters in Real Practice

Symptom clusters and pharmacotherapy targets
Perimenopause vs menopause prescribing implications
PK/PD and route differences: oral vs transdermal vs local therapy
Candidate selection, shared decision-making, and risk stratification

Evidence-Based Prescribing Across Menopause and Midlife

Systemic estrogen options: Indications, dosing concepts, route selection
Endometrial protection: Micronized progesterone, progestins, LNG-IUS considerations
Nonhormonal prescription therapies for vasomotor symptoms
Genitourinary syndrome of menopause: Local hormonal and nonhormonal options

Advanced Clinical Application and Special Populations

Breast risk, VTE risk, migraine, obesity, hypertension, metabolic disease
Sexual symptoms, sleep, mood, and layered prescribing decisions
Case-based medication selection and sequencing
Limitations of the research and potential risks

Target Audience

NPs
APRNs
CNSs
PAs
MDs
PharmDs – Primary Care/Family Practice

Copyright : 09/24/2026

Beyond the Benzodiazepine: Updated Psychopharmacology for Anxiety, Sleep Disorders, and the Overactive Mind

Anxiety disorders and insomnia are among the most prevalent conditions encountered in clinical practice, yet both are frequently mismanaged. Despite decades of prescribing experience, clinicians continue to face mounting pressure to move away from benzodiazepines and sedative-hypnotics while navigating a rapidly expanding formulary of newer agents whose evidence base is still evolving. This session cuts through the noise, offering a clinically rigorous, pharmacology-first approach grounded in current guidelines. Stephanie L. Shafer, DHSc, MSN, PMHNP-BC, ANP-BC, will break down the latest sleep guidelines specifically, including the American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment and the VA/DoD insomnia guideline.

This advanced-level training moves beyond traditional algorithms to provide a clinically grounded, mechanism-based approach to medication decision-making frameworks needed to select, sequence, and adjust medications with greater confidence and safety. Match pharmacologic strategies to specific symptom patterns, including hyperarousal, cognitive overactivity, and disrupted sleep architecture. Practical tools will be provided to improve outcomes, minimize risk, and confidently manage complex presentations involving anxiety, insomnia, and overlapping psychiatric and medical comorbidities.

Program Information

Objectives

By the end of this lecture, attendees will be able to:

Apply mechanism-based pharmacologic strategies to optimize treatment selection for patients with anxiety and insomnia, particularly in complex or treatment-resistant presentations.
Evaluate medication-related risks, interactions, and patient-specific variables to improve safety, tolerability, and clinical outcomes in real-world prescribing.

Outline

Part I: Mechanistic Foundations-Neurobiology and Pharmacologic Targets in Anxiety and Insomnia

Review common comorbidities and potential differential diagnoses
Discuss medication classes and differentiating factors in terms of mechanism of action: classes (BZDs, SSRIs/SNRIs, buspirone, Z-drugs, DORAs, melatonin agonists, hydroxyzine, etc.)
Hyperarousal model and CNS overstimulation
Neurotransmitter systems/receptor targets: GABAergic, serotonergic, noradrenergic, and orexinergic pathways relevant to sleep and anxiety

Part II: Clinical Pharmacotherapeutics-Strategic Evidence-Based Selection and Optimization

Updated guidelines: Anxiety disorders and insomnia treatment hierarchy, FDA labeling changes for Z-drugs and DORAs
What drives prescribing decisions: First-line vs next-step pharmacotherapy: when to move beyond SSRIs
Adjunctive and augmentation strategies (buspirone, atypical antipsychotics, etc.)
Insomnia-specific agents: dual orexin receptor antagonists, Z-drugs, melatonin agonists
Polypharmacy decision-making: augmentation vs switching strategies

Part III: Drug Safety, Special Populations, and Deprescribing

Benzodiazepine risk stratification: Dependence, cognitive effects, fall risk, etc.
Adverse effects: sedation, cognitive impairment, dependence risk
Special populations/considerations: older adults, TBI, comorbidity burden

Target Audience

APRNs
PAs
MDs
Dos
PharmDs

Copyright : 09/24/2026

Abdominal Pain: Current Guidelines for H Pylori, Diverticulitis, Gastroparesis, and Non-GI Conditions

Abdominal pain is one of the most diagnostically treacherous presentations in primary care - and the stakes are high when a ruptured AAA gets charted as constipation or an MI patient walks in holding their stomach. This session cuts through the overlapping features with a case-based, systems-level approach that covers both the obvious and the easily missed.

You'll work through updated pharmacology for H. pylori eradication, including vonoprazan-based regimens, rifabutin, and quadruple therapy, plus the shifting evidence on antibiotics in uncomplicated diverticulitis, current gastroparesis management, and non-GI masqueraders every prescriber needs on their radar.

Peter Buch, MD, AGAF, FACP brings clinical gastroenterology precision to the cases you're already seeing - and the prescribing decisions you need to make confidently, right now.

Program Information

Objectives

Evaluate current and emerging H. pylori treatment regimens - including vonoprazan-based protocols, rifabutin, and quadruple therapy options - and apply antimicrobial sensitivity principles to optimize eradication rates and reduce treatment failure.
Analyze the evolving evidence on antibiotic use in uncomplicated diverticulitis and apply current literature to clinical decision-making around antibiotic selection, omission, and recurrence prevention.

Outline

Non-GI Sources of Abdominal Pain

Abdominal Aortic Aneurysm Rupture
- Missed diagnosis in 32% of patients, due to overlap with other illnesses
More Sources of Abdominal Pain
- Hernias
- MI
- Pulmonary emboli
- Herpes zoster
- Ectopic pregnancy
- Muscular source of abdominal pain
- Case scenarios for the above

GI Sources of Abdominal Pain

Gastroparesis
- Diagnosis
- What is the most common source of gastroparesis?
- Current treatments and controversies
H Pylori
- Diagnosis and pitfalls
- Antimicrobial sensitivity: When, how, and why
- Current treatments
  - Clarithromycin???
  - Quadruple therapy options
  - Rifabutin
  - Vonoprazan
  - Vonoprazan based options
- Reinfection rates/treatment failures
- Should we be retesting for the eradication of Helicobacter after treatment?
- Pitfalls of retesting
Diverticulitis
- Categories: Uncomplicated/Complicated
- Accuracy of diverticulitis diagnosis based on history, exam and routine
- Lab tests to order
- CT frequency in patients with suspected diverticulitis
- Fiber and diverticulitis
- Do nuts, seeds and popcorn cause diverticulitis
- Medications that exacerbate diverticulitis
- Colonoscopy decisions for patients with diverticulitis
- Colonoscopy guidelines for recurrent diverticulitis
- Uncomplicated cases of diverticulitis may not need antibiotics
- Review of literature and decision making guidance
- When surgery is needed for uncomplicated and complicated diverticulitis
- Preferred antibiotic therapy to prevent recurrent diverticulitis

Target Audience

NPs category 200, 201, 202, 203, 205, 221, 226,228,231,232,238, 245
APRNs
CNs
PAs
MDs
PharmDs
Primary Care/Family Practice

Copyright : 09/24/2026

Artificial Intelligence (AI) for Clinical Decision-Making: Opportunities & Pitfalls for Prescribers

In this presentation, the promises and pitfalls of artificial intelligence (AI) for clinical decision-making will be discussed. While AI has shown great promise in tools like automated scribes to capture clinical notes, early warning systems, and complex diagnostic cases, advanced clinical reasoning for treatment remains a domain that requires thoughtful assessment by prescribers at the frontlines. This presentation will discuss the regulatory environment of AI tools (and the important role of stakeholders like clinicians), common pitfalls of reliance (and overreliance) on AI tools, and the latest research for understanding how language reasoning models may be integrated into clinical practice. By the end of this presentation, prescribers will have a set of best practices for the use of clinical AI.

Program Information

Objectives

Distinguish between evidence-supported and high-risk uses of AI in clinical decision-making, applying knowledge of hallucinations, sycophancy, and current FDA and regulatory perspectives to protect patient safety.
Apply the ABC Framework and current medication-specific LLM benchmarking evidence to critically appraise AI tools and AI-focused literature before integrating them into prescribing practice.

Outline

How AI Actually Works and Why It Matters for Prescribers

How large language models predict and generate text - and why that matters clinically
What AI can genuinely do in healthcare: passing medical exams, flagging sepsis early, interpreting diagnostic cases
Why understanding the mechanics helps you use the tools more safely

AI Dangers in Practice: What You Should Look For

FDA and JAMA perspectives on AI tool regulation: Where the guardrails are (and aren't)
Hallucinations: What they are, why they happen, and how to spot them in clinical context
Sycophancy: When AI tells you what you want to hear, instead of what's accurate
The "confidently wrong" problem and what's being done about it
If AI can diagnose, what is the clinician’s role? What do we risk losing?

AI and Medications: What the Evidence Actually Shows

How do LLMs perform medication-specific tasks? What the research reveals
General-purpose AI tools may not be reliable for prescribing decisions - and what to look for instead
Critically evaluate any AI tool or AI-focused article before using it in practice
The ABC Framework: A practical construct for assessing AI output quality
Applying a clinical journal club approach: Use real cases to stress-test AI recommendations before you trust them

Target Audience

NPs
APRNs
CNSs
PAs
MDs
PharmDs – Primary Care/Family Practice

Copyright : 09/24/2026

Own the Neuro Complaint: Red Flags, Real Workups, Right Referrals

Copyright : 09/25/2026

Beyond Weight Loss: Practical Obesity Pharmacotherapy Algorithms for Better Cardiometabolic Care

Obesity pharmacotherapy is evolving rapidly, and experienced frontline clinicians need more than a list of medications; they need a practical prescribing framework. Newer GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and now oral incretin options are changing how clinicians think about obesity treatment, not only for weight reduction but also for cardiometabolic risk, diabetes prevention, and related complications such as obstructive sleep apnea. Recent developments include cardiovascular outcomes data for semaglutide in patients with obesity without diabetes, head-to-head evidence comparing tirzepatide with semaglutide, the 2025 oral semaglutide obesity data set, and the April 2026 FDA approval of oral orforglipron for chronic weight management.

This presentation will help clinicians make more confident, evidence-based prescribing decisions in complex clinical settings. It will focus on the practical challenges that affect outcomes in routine care: identifying the right candidate for treatment, choosing among injectable and oral therapies, counseling about adverse effects and expectations, monitoring response, navigating contraindications and safety warnings, and planning for maintenance or therapy transition. It will also address the limitations of the current evidence base, including generalizability, durability, comparative gaps, and the reality that access, adherence, and tolerability often determine whether trial-level benefits translate into clinical practice.

Program Information

Objectives

Apply current obesity pharmacotherapy algorithms to select and sequence GLP-1 receptor agonists, dual agonists, and novel oral agents based on comorbidities, treatment goals, and patient-specific risks.
Interpret recent obesity-treatment evidence to improve real-world clinical outcomes while recognizing safety considerations, evidence limitations, and implementation barriers.

Outline

Obesity Pharmacotherapy in 2026: From Weight Loss to Cardiometabolic Risk Reduction

Obesity is a chronic, relapsing, cardiometabolic disease
Current treatment algorithms and where medications fit
GLP-1 agonists, dual agonists, and novel oral agents: Mechanism and clinical role
Shift from BMI-only thinking to outcome-oriented prescribing

Practical Prescribing Algorithms for GLP-1 Agonists, Dual Agonists, and Novel Oral Therapies

Patient selection by phenotype, comorbidities, and treatment goals
Choosing an appropriate agent for a specific patient presentation
Titration, counseling, adverse effect mitigation, follow-up
Switching, maintenance, discontinuation, and weight-gain planning

Applying the Evidence in Real-World Obesity Care

Cardiovascular outcomes, diabetes prevention, obstructive sleep apnea, and other comorbidity benefits
Contraindications, boxed warnings, monitoring, and special populations
Access, coverage, adherence, and implementation barriers
Limitations of the research and potential risks

Target Audience

NPs
APRNs
CNSs
PAs
MDs
PharmDs – Primary Care/Family Practice

Copyright : 09/25/2026

Align Hypertension Treatment with Guideline-Directed Heart Failure Therapies

Hypertension is one of the most common chronic conditions managed in primary care and a leading contributor to heart failure and cardiovascular disease. Despite clear evidence supporting treatment, many patients remain uncontrolled due to therapeutic inertia, complex medication regimens, and evolving clinical recommendations. Updates from the American Heart Association and American College of Cardiology introduce important shifts in how clinicians assess risk, initiate therapy, and monitor patients, placing primary care providers at the center of prevention and early intervention.

This session is designed for primary care clinicians, focusing on practical strategies to improve outcomes. Attendees will learn how to integrate the PREVENT risk calculator into routine visits, initiate antihypertensive therapy earlier, and select medications that not only lower blood pressure but also align with guideline-directed management of heart failure. By emphasizing simplified treatment pathways, combination therapy, and real-world prescribing considerations, this session equips clinicians to reduce cardiovascular risk and prevent progression to heart failure.

Program Information

Objectives

Apply new American Heart Association / American College of Cardiology hypertension guidelines to initiate and optimize individualized treatment plans, including use of the PREVENT risk calculator and stage-based pharmacologic strategies.
Select and manage antihypertensive therapies that align with cardiovascular and heart failure risk reduction, incorporating combination therapy, appropriate laboratory monitoring, and safety considerations in diverse primary care populations.

Outline

Guideline Updates and Risk Assessment in Primary Care

Key AHA/ACC updates relevant to outpatient care
Blood pressure goals and treatment targets
PREVENT calculator, application during routine visits
Identify patients at risk for CVD and heart failure earlier

Pharmacological Management of Hypertension and Heart Failure Integration

Stage 1 vs Stage 2 HTN: When to initiate therapy
Medication selection aligned with heart failure benefit
Single-pill combination therapy: Adherence and BP control
Early use of agents with dual benefit (BP + HF risk reduction)
Drug safety, adverse effects, and interaction management

Implementing Best Practices in the Real World

Monitoring labs for therapeutic and safety considerations with cardiovascular medications
Overcoming therapeutic inertia and time constraints
Patient adherence strategies and shared decision-making
Limitations of the research and potential risks

Target Audience

NPs
APRNs
CNSs
PAs
MDs
PharmDs – Primary Care/Family Practice

Copyright : 09/25/2026

Managing T1D Between Endocrinology Visits: Insulin Pharmacology, CGM Interpretation, and the PCP’s Expanding Role

Type 1 diabetes doesn't stay in the endocrinologist's office - it shows up on your panel, and PCPs are increasingly expected to co-manage it. This session gives you practical pharmacology and clinical tools to do that confidently. You'll work through the 2026 ADA standards for autoantibody screening, learn how to differentiate insulin types and apply carbohydrate ratios and insulin sensitivity factors used in real-world dose titration, and get familiar with the technology your patients are already using - CGMs and automated insulin delivery systems. Whether you're supporting a stable T1D patient between endocrinology visits or navigating a new diagnosis, you'll leave with a clear, actionable framework for managing type 1 diabetes in primary care.

Program Information

Objectives

Differentiate the co-management responsibilities of primary care in the ongoing care of patients with type 1 diabetes, including criteria for escalation and referral.
Explain insulin pharmacology principles that PCPs need to understand, including carbohydrate ratios and insulin sensitivity factors.
Interpret ambulatory glucose profile (AGP) data from continuous glucose monitors to guide clinical decision-making in the primary care setting.

Outline

Type 1 vs. Type 2: Getting the Diagnosis Right

Key pathophysiological differences between T1D and T2D, including LADA
ADA autoantibody screening recommendations: who to test and when
Teplizumab for T1D delay: what PCPs need to know about early intervention

The PCP's Role in T1D Co-Management

Defining the primary care scope: what to own vs. when to refer

Recognizing and managing common T1D complications in the primary care setting

Insulin Pharmacology for Primary Care

Insulin types demystified: ultra-rapid, rapid, regular, NPH, long-acting, and once-weekly options
Dose calculations PCPs need to know: carbohydrate ratios and insulin sensitivity factors

Diabetes Technology: Interpreting and Managing in Primary Care

Continuous glucose monitors: patient setup, education, and AGP interpretation
Insulin pumps and automated insulin delivery systems: how they work and what PCPs need to monitor
Using CGM data to drive clinical decisions at primary care visits

Putting It Together: Confident T1D Management in Your Panel

Applying the 2026 ADA Standards to your primary care practice
Patient education priorities PCPs can own
Identifying red flags that warrant urgent endocrinology escalation

Target Audience

NPs
APRNs
CNSs
PAs
MDs
PharmDs – Primary Care/Family Practice

Copyright : 09/25/2026

The Geriatric Prescriber’s Reality: Clinical Decision Making, Cost Navigation, and Safer Medication Use in Adults 65+

Copyright : 06/09/2026

Rethinking Food Allergy: Accurate Diagnosis, Evidence-Based Anaphylaxis Management, and Biologic Integration

Copyright : 06/16/2026

Sleep Disordered Breathing and Management for PCP

Copyright : 06/05/2026

Integrating Prescription and Cosmetic Skincare into Your Practice

This course provides healthcare professionals with essential knowledge on prescription and over-the-counter medication classifications, including safety and efficacy. Participants will explore common dermatological diagnoses, management strategies for female hair loss and eyelashes, and advanced skincare treatments. Be prepared to grow your practice and confidently optimize outcomes in cosmetic dermatology.

Program Information

Objectives

Evaluate available prescription skincare options
Discuss principles of pharmacological management of skin care.
Analyze patient specific presentations that contribute to therapeutic selections.

Outline

Prescription v over-the-counter medication classification
- Supplement safety
- Placebo response
10 most common derm diagnosis
Topical Corticosteroids
- Use, side effects, vehicles
- Oral choice
- Aluminum acetate
Acne prescriptive skin care
- Acne mild v moderate
- Oral isotretinoin
  - HTG
  - ipledge
- Actives to avoid
- Azelaic acid
- Salicyclic acid
- Topical and oral antibiotics
- Benzoyl peroxide
- antiandrogens
Rosacea prescriptive skin care
- First line agents and triggers
- Second line treatments
Additional skin care
- AHA & BHA
- Niacinamide
- Topical hydroquinone
- Tranexamic acid
Topical estrogen for skin care
Bimatoprost
- Use, side effects, permanent v reversible AE
Female pattern hair loss
- Therapeutic goals
- Education on treatment expectations
- Minoxidil
- Spironolactone
- Finasteride
- Ketoconazole
- Second line treatments
Drug Rashes
- Epidemiology, presentation, treatment
Marketing new skills
Conclusion

Target Audience

Nurses
Nurse Practitioners
Physician Assistants
Doctors of Osteopathic Medicine
Medical Doctors
Clinical Nurse Specialists

Copyright : 10/07/2024

Pain and Migraine Prescribing Update: CGRP Therapies, Novel Analgesics, and Real-World Clinical Challenges

Copyright : 06/12/2026

Rising Resistance, Long-Acting Solutions: A Pharmacology Update for STI and HIV Management

Copyright : 06/29/2026

Realize the Potential of Rapid-Acting Treatments for Depression

Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. Monoaminergic antidepressants, which are currently considered the standard of care, have several limitations, including low therapeutic response rates, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence. Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP will explore novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. Discover when newer pharmacologic agents, including neuroactive steroids and glutamatergic antidepressants are appropriate. Take away practical prescriptive considerations and apply them to real-world cases.

Program Information

Objectives

Advance your understanding of the mechanisms of action for novel rapid-acting pharmacotherapies for depression.
Evaluate the efficacy and unique safety profiles associated with novel antidepressants.
Select appropriate patients for treatment with rapid-acting antidepressants.
Explain the skills needed to engage in shared decision making to optimize patient outcomes.

Outline

Novel Rapid-Acting Pharmacotherapies for Depression: Mechanisms of Action

Treatment-as-usual
Unmet needs
MDA receptor antagonists
Neuroactive steroid GABA-A modulators

Efficacy and Unique Safety Profiles Associated with Novel Antidepressants

Neurobiology of depression, revisited (GABA/glutamate)
Clinical studies and outcomes

Select Appropriate Patients for Treatment with Rapid-Acting Antidepressants

Case applications
TRD/anhedonia
PPD
Suicidality

Shared Decision Making to Optimize Patient Outcomes

Shared decision-making with patients
Case applications, continued

Target Audience

Nurse Practitioners
Nurses
Physician Assistants
Physicians
Pharmacists

Copyright : 10/25/2024

Management of Atrial Fibrillation

The American College of Cardiology/American Heart Association/American College of Clinical Pharmacy/Heart Rhythm Society released a new updated guideline for the diagnosis and management of atrial fibrillation (AF) at the end of 2023. The previous classification of AF was based on arrhythmia duration which highlighted AF after it was diagnosed. The guideline also emphasizes the importance of early rhythm control. Some patients develop AF during surgery or acute illness, and the guideline provides recommendations for the management of these patients. Patients with AF have an increased risk of stroke. There are various thromboembolism prevention strategies. The use of wearable devices has increased and can lead to a diagnosis of AF.

When caring for a patient with AF, deciding between rate control or rhythm control is important but can change over time and involves shared decision making. Both are reasonable strategies and based on several factors. There are pharmacological options as well as non-pharmacological options. Specific patient groups require additional considerations when deciding on treatment options. Considerable progress has been made in the prevention and management of AF in recent years.

Program Information

Objectives

Incorporate the newly released classification of atrial fibrillation into practice.
Determine thromboembolism prevention strategies.
Evaluate pharmacology and non-pharmacology options for a rate control strategy.
Analyze pharmacology and non-pharmacology options for a rhythm control strategy.
Review additional considerations for specific patient groups with atrial fibrillation.

Outline

Atrial fibrillation classification
Mechanisms and pathophysiology
Clinical evaluation
Lifestyle and risk factor modification

Primary prevention
Secondary prevention

Thromboembolism prevention

Pharmacological

Anticoagulants
Reversal agents

Nonpharmacological

Percutaneous LAA occlusion device
Cardiac surgery

AHRE
Periprocedural management
Special populations

Rate control strategy

Pharmacological treatment
Nonpharmacological treatment

Rhythm control strategy

Cardioversion

Electrical
Pharmacological

Antiarrhythmic drugs
Catheter ablation
Surgical ablation
Role of pacemakers and ICDs

Special patient groups
Patient education

Target Audience

Physicians
Physician Assistants
Nurses

Copyright : 12/13/2024

Overcoming Urinary Issues in Older Age

During this session, Susann Varano, MD, will identify the most common urinary issues encountered in the older adult and review the latest recommendations presented at the May 2024 American Urological Association meeting. Once we have properly diagnosed the urinary issue, we will comprehensively evaluate the patient to prescribe a non-pharmacological or pharmacologic treatment plan. We will discuss risk factors in the older adult for urinary incontinence. You will conclude the training with ways to overcome environmental barriers to incontinence management in dementia patients. Leave with new tools and insights to aid in the diagnosis and management of urinary issues in the older adult.

Program Information

Objectives

Summarize the aging process and how it relates to bladder health.
Explore urinary incontinence in the cognitively impaired older adult.
Explain the overactive bladder diagnosis and comprehensively explore treatment options.
Review the May 2024 American Urological Association meeting treatment recommendations for overactive bladder.

Outline

Lower Urinary Tract Conditions

Persons at risk
Root cause
Bladder health
Preventing urinary incontinence in women
Burdens of urinary incontinence

Nocturia

Overactive bladder (OAB)

Implications associated with OAB
Challenges associated with OAB
Treatment plan for overactive bladder
Outpatient Treatment
Long term care treatment
Nonpharmacologic
Pharmacologic

Target Audience

Nurses
Nurse Practitioners
Clinical Nurse Specialists
Physician Assistants
Physical Therapists
Physical Therapist Assistants
Occupational Therapists
Occupational Therapy Assistants
Speech-Language Pathologists
Social Workers
Counselors
Nursing Home Administrators
Physicians

Solutions for Common Sleep Disturbances in Women

Join Nicole Pezzino PharmD, BCACP, CDCES for an insightful two-hour session dedicated to exploring common sleep disturbances for women. This session will delve into the complexities of sleep disorders that affect women, providing underlying causes and impact on overall health. Providers will gain a deeper understanding of pharmacological approaches used in managing sleep disturbances specific to women, including considerations for hormonal influences, medication interactions, and patient-centered treatment strategies. Through case studies and evidence-based discussions, learn practical insights and tools essential for optimizing patient care in women's sleep health.

Program Information

Objectives

Identify key factors contributing to sleep disorders in women.
Compare evidence-based pharmacological treatments available for managing sleep disturbances in women.
Evaluate non-pharmacological interventions and lifestyle modifications that can complement pharmacological treatments for sleep disorders.
Develop patient-centered strategies for counseling and educating women on sleep hygiene practices and treatment options.

Outline

Key Factors Contributing to Sleep Disorders in Women

Hormonal influences: Impact of menstrual cycles, pregnancy, and menopause on sleep
Psychosocial factors: Stress, anxiety, substance use disorders and posttraumatic stress disorders affecting women's sleep patterns

Pharmacological Treatments for Sleep Disorders in Women

Pharmacological options: benzodiazepine receptor agonists (BZRAs) (including nonbenzodiazepines and benzodiazepine hypnotics), dual orexin receptor antagonists (DORAs), low-dose doxepin, ramelteon
Off label prescription medications prescribed for insomnia and over-the counter sleep aids (i.e., diphenhydramine and doxylamine)
Dietary supplements (i.e., melatonin, valerian, kava, magnesium) and cannabinoids
Choosing medications based on specific sleep disorders and patient characteristics (side effect profiles, cost, clinician/patient preferences)

Non-Pharmacological Interventions & Lifestyle Modifications

Importance of sleep hygiene practices: Establishing a consistent sleep schedule, optimizing sleep environment
Cognitive-behavioral therapy for insomnia (CBT-I): Techniques and effectiveness
Lifestyle modifications: Exercise, diet, and stress management techniques to improve sleep quality

Case Studies and Clinical Applications

Presentation of case studies demonstrating the integration of pharmacological and non-pharmacological treatments

Patient-Centered Counseling and Education

Effective communication strategies for discussing sleep disorders with women
Providing information on sleep hygiene practices and treatment options tailored to individual needs
Addressing patient concerns and fostering adherence to treatment plans

Target Audience

Nurse Practitioners
Nurses
Physician Assistants
Physicians
Pharmacists

Medical Assisted Dying

In this 1-hour session, Dr. Stefanie Greene, a pioneering practitioner of assisted dying, will give an overview of medical aid in dying in the United States today. The session aims to clarify what aid in dying is and how it came to be available in some parts of the Country but not others. Content will include how this practice works; the process involved and highlight what changes could be coming.

Dr. Green will share some data: looking at people’s attitudes towards assisted dying, who is accessing this care, and what their reasons are for doing so. She will highlight some of the lessons learned to date. Before leaving time for questions from learners, Dr. Green will reflect on her personal experience with this work; why she continues to do it, and how it has affected her own life.

Program Information

Objectives

Differentiate between the terminologies used for assisted dying.
Compare both access and processes with respect to assisted dying within the United States today.
Analyze how medical assisted dying might have an impact on one’s personal and professional life.
Evaluate who is accessing medical assisted dying and their reasons.

Outline

Medical Assisted Dying

Terminology and international context
Data on attitudes
How medical assisted dying came to be available in the U.S.

Assisted Dying Within the United States

Who can access this care today and how it works
Highlighted differences between jurisdictions
a glance into what the future might hold

What We’ve Learned

Data: Who is accessing the care and their reasons
Is there cause for concern?

Why Do This Work?

Personal reflection

Target Audience

Social Workers
Nurses
Physicians

Innovative Cost-Conscious Prescriptive Decisions in Chronic Disease Treatment

Be inspired to make positive changes in underserved and low-income healthcare, promoting cost-conscious decisions without sacrificing quality care. Martha Ndung’u, PharmD will share her expertise and passion for innovative cost-conscious prescriptive strategies, databases and tools for cost analysis, drug formulary selection, and real-world successes. You will be empowered with the knowledge and skills to make cost-conscious decisions in chronic disease treatment.

Program Information

Objectives

Explore the economic impact of chronic diseases and their management in underserved and low-income patients.
Evaluate the cost-effectiveness of treatment options for chronic diseases.
Discover innovative approaches to managing chronic diseases on a limited budget.
Acquire practical tools and resources for making cost-conscious decisions in treatment.

Outline

Economic Impact of Chronic Diseases

The burden of chronic diseases
Significance of underserved and low-income healthcare
Cost breakdown of managing chronic diseases
Pharmacoequity: The challenges of cost-effective care

Cost-Effective Analysis

Principles of cost-effectiveness analysis
Case studies: Comparing treatment options
Identifying high-value interventions

Innovative Strategies for Cost-Conscious Care

Leveraging technology and community partnerships
Collaborative care models
Patient education and self-management

Real-World Success Stories

Showcase cost-conscious programs
Lessons learned from global healthcare initiatives

Practical Tools and Resources

Accessible databases and tools for cost analysis
Drug formulary selection and utilization
Patient-centered decision-making

Show Me the Money as a Legal Nurse Consultant

Lorie A. Brown, RN, MN, JD, will share tips and secrets to establish or grow your legal nurse consultant business. Attorney Brown coaches LNCs around the country to perform at their best in this lucrative career path.

This session will provide valuable insights on how you will be able to work less while successfully making a difference. Take away brand new insights and discover the ways you can earn more than you make at your current day job!

Program Information

Objectives

Analyze the roadblocks that could affect a successful legal nurse consultant business.
Plan steps to become successful as a LNC.
Create a new money mindset around charging for your services.

Outline

Overcome mental blocks and disbeliefs
Push past fears
Create a plan on what to charge in your business – initially and as you excel
Embody a positive money mindset
Break the limiting rules you set for your business
And MORE!

Target Audience

Nurses
Nurse Practitioners
Clinical Nurse Specialists
Advanced Practice Registered Nurses
Risk Managers
Legal Nurse Consultants
Attorneys

Preparing for Infectious Disease Season in the Geriatric Population: Pharmacologic Approaches to Respiratory Infections

Respiratory illnesses can cause serious complications, especially in high-risk populations like geriatrics. This presentation will review antimicrobials available for influenza, COVID-19, and bacterial community-acquired pneumonia management, as well as their associated pharmacologic features. Recent efficacy and safety evidence will be reviewed and assessed for insights into optimizing appropriate use in clinical practice.

Program Information

Objectives

Compare and contrast clinically relevant antimicrobial related factors such as mechanism of action, duration of action, side effects, and spectrum of activity.
Choose effective antibiotic therapies that minimize risk for adverse effects in the geriatric population.
Develop risk factor–based empiric antibiotic regimens for geriatric respiratory infections.
Discriminate clinical scenarios requiring initiation of single versus combination antibiotic therapy for pneumonia in the community.

Outline

Etiologic Considerations for Geriatric Respiratory Infections

Pharmacologic Management of Influenza

Compare and contrast oseltamivir and baloxavir marboxil
Pharmacologic efficacy in geriatrics

Therapeutic Considerations for COVID-19

Compare and contrast nirmatrelvir/ritonavir, remdesivir, molnupiravir
Overview recent real-world outcome data

Bacterial Pneumonia

Advantages and disadvantages of commonly prescribed agents
Monotherapy versus combination therapy

Target Audience

Nurses
Nurse Practitioners
Clinical Nurse Specialists
Physician Assistants
Physical Therapists
Physical Therapist Assistants
Occupational Therapists
Occupational Therapy Assistants
Social Workers
Physicians